Online inquiry

IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9390MR)

This product GTTS-WQ9390MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets IL2R gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000417.3; NM_000878.5; NM_000206.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3559; 3560; 3561
UniProt ID P01589; P14784; P31785
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9390MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6635MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DI-17E6
GTTS-WQ4472MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ9960MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA KBSA301
GTTS-WQ7208MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ604MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ1076MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-838
GTTS-WQ4859MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ41MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 2857916
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW